Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure: Final appraisal document

In DRAFT guidance, NICE recommends the use of avatrombopag as an option for treating severe thrombocytopenia (platelet count of below 50,000 platelets per microlitre of blood) in adults with chronic liver disease having planned invasive procedures.

National Institute for Health and Care Excellence